Legend Biotech Corp
NASDAQ:LEGN
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
37.42
69.99
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Legend Biotech Corp
Legend Biotech Corp
Cost of Revenue
Legend Biotech Corp
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Legend Biotech Corp
NASDAQ:LEGN
|
Cost of Revenue
-$144.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cost of Revenue
-$18.2B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-15%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cost of Revenue
-$6.3B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-6%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cost of Revenue
-$12.9B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-13%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cost of Revenue
-$1.5B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-36%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cost of Revenue
-$1.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-25%
|
|
Legend Biotech Corp
Glance View
Legend Biotech Corp. is a pioneering biotechnology company that has made significant strides in the field of cell therapy, particularly with its innovative approaches to treating cancer. Founded in 2014 and based in Somerset, New Jersey, Legend is at the forefront of developing advanced therapies that harness the power of the immune system. At the heart of its mission is its flagship product, a revolutionary chimeric antigen receptor T-cell (CAR-T) therapy aimed at targeting and eliminating cancer cells. Following promising clinical results, the company has attracted attention from investors looking for high-growth opportunities in the ever-evolving biotech landscape. With strategic partnerships, including a noteworthy collaboration with Johnson & Johnson's Janssen division, Legend is set to leverage substantial resources towards the commercialization of its therapies. For potential investors, Legend Biotech represents both opportunity and risk, typical of the biotechnology sector. The company operates in a competitive market but has positioned itself with a promising pipeline and a robust intellectual property portfolio that supports its growth initiatives. Its focus on personalized medicine not only aligns with current healthcare trends but also offers the potential for high returns, especially as the demand for effective cancer treatments continues to rise. As Legend progresses through clinical trials and moves towards regulatory approvals, investors will be keenly watching its developments, as successful outcomes could significantly enhance its market position and drive its stock value upward.
See Also
What is Legend Biotech Corp's Cost of Revenue?
Cost of Revenue
-144.2m
USD
Based on the financial report for Dec 31, 2023, Legend Biotech Corp's Cost of Revenue amounts to -144.2m USD.
What is Legend Biotech Corp's Cost of Revenue growth rate?
Cost of Revenue CAGR 1Y
-121%
Over the last year, the Cost of Revenue growth was -121%.
You don't have any saved screeners yet
